{
    "eid": "2-s2.0-85105062344",
    "title": "Extended thromboprophylaxis for medically ill patients with cancer: A systemic review and meta-analysis",
    "cover-date": "2021-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Soravis Osataphan",
        "Rushad Patell",
        "Thita Chiasakul",
        "Alok A. Khorana",
        "Jeffrey I. Zwicker"
    ],
    "citedby-count": 7,
    "ref-count": 34,
    "ref-list": [
        "Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US",
        "Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism: A cohort study",
        "Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: A systematic review and meta-analysis",
        "Extended thromboprophylaxis with direct oral anticoagulants for medical patients: A systematic review and meta-analysis",
        "American Society of Hematology 2018 guidelines for management of venous thromboembolism: Prophylaxis for hospitalized and nonhospitalized medical patients",
        "Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment",
        "Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: A systematic review and meta-analysis",
        "Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy",
        "Incidence of venous thromboembolism in patients hospitalized with cancer",
        "Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis",
        "Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH",
        "Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients",
        "Rivaroxaban for thromboprophylaxis after hospitalization for medical illness",
        "Rivaroxaban for thromboprophylaxis in acutely ill medical patients",
        "Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: A randomized trial",
        "Extended thromboprophylaxis with betrixaban in acutely ill medical patients",
        "Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: Insights from the APEX trial",
        "Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer",
        "Apixaban to prevent venous thromboembolism in patients with cancer",
        "Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery",
        "Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge",
        "Bleeding and venous thromboembolic events in patients with active cancer hospitalized for an acute medical illness",
        "Identifying predictors for bleeding in hospitalized cancer patients: A cohort study",
        "DOACs vs LMWHs in hospitalized medical patients: A systematic review and meta-analysis that informed 2018 ASH guidelines",
        "Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer",
        "Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: A randomized, double-blinded multicenter phase 2 trial",
        "Long-term risk of venous thromboembolism in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study",
        "Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: A population-based cohort study using multiple linked UK electronic health records databases",
        "Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool",
        "A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey",
        "Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis",
        "Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers",
        "Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial",
        "Apixaban for the treatment of venous thromboembolism associated with cancer"
    ],
    "affiliation": [
        {
            "affiliation-city": "Boston",
            "@id": "60002746",
            "affilname": "Harvard Medical School",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002746",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Cleveland",
            "@id": "60032732",
            "affilname": "Taussig Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032732",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Institutes of Health",
        "National Heart, Lung, and Blood Institute"
    ]
}